Soon To Be Phase 1 Trial: EIK1006, a Next-Generation Androgen Receptor Antagonist

A new experimental drug, EIK1006, has received clearance from the U.S. Food and Drug Administration (FDA) to enter clinical testing in patients with advanced metastatic prostate cancer. Announced on November 17, 2026, the authorization allows the initiation of ARGATE-001, a Phase 1/2 trial investigating a next-generation androgen receptor (AR) antagonist designed to overcome resistance to existing hormone-directed therapies.

Resistance to androgen receptor pathway inhibitors (ARPIs), including enzalutamide, apalutamide and darolutamide, remains a major challenge in metastatic prostate cancer. Over time, cancer cells can develop genetic alterations that allow androgen receptor signaling to continue despite treatment. These include AR gene amplification and mutations affecting the receptor’s ligand-binding domain, potentially reducing the effectiveness of conventional AR antagonists.

EIK1006 is designed to address some of these resistance mechanisms. Unlike androgen receptor degraders, such as PROTAC-based therapies, EIK1006 acts as an antagonist. Preclinical research indicates that it binds to the androgen receptor’s ligand-binding domain and prevents the receptor from moving into the cell nucleus, where it would normally activate genes involved in cancer growth.

Importantly, the compound has demonstrated preclinical activity against both normal androgen receptors and several clinically relevant AR variants associated with resistance to existing treatments. This raises the possibility that EIK1006 could remain effective in certain tumors that have progressed despite previous ARPI therapy.

The upcoming ARGATE-001 study will evaluate EIK1006 in patients with metastatic prostate cancer whose disease has progressed following established hormone-directed treatment. As a first-in-human Phase 1/2 trial, its initial objectives will include assessing safety, tolerability and preliminary antitumor activity.

Source.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply